

PharmaMar's 2017 Group Annual General Shareholder's' meeting

- The ATLANTIS study's overall survival data for Zepsyre® (lurbinectedin) will be known at the end of 2019.
- PharmaMar is negotiating with different companies from the sector, new studies with lurbinectedin in combination with immunotherapy.
- Sylentis will present results of the phase III study for dry eye syndrome during the last quarter 2018 and will proceed with the studies of two other molecules for the treatment of macular degeneration and eye allergies.
- The CLART® HPV Diagnostic Kit for Human Papillomavirus (HPV) opens for business on the Korean market.
- The biopharmaceutical sector's income is 60% of the Group's total income.
- The Group's consumer chemical sector plans to continue with its strategy for growth.

Vigo, 28th June 2018. The PharmaMar Group holds today its Annual General Shareholders' Meeting in Vigo, where it will review the results for 2017, and go over the most important milestones for this period, along with the future plans for the Company, above all in the area of oncology with its molecules at different stages of clinical development.

The Oncology Business Unit

Small-Cell Lung Cancer is PharmaMar's priority research area. Zepsyre® (lurbinectedin) is at a phase III investigational stage, with its ATLANTIS study for the treatment of this type of tumor. PharmaMar hopes to finalize recruitment in the third quarter of 2018, and to have the final data on overall survival during the second half of 2019.

PharmaMar has also presented for the same indication, positive data of the phase II study trial with lurbinectedin as monotherapy during the American Congress of Clinical Oncology (SCO) held recently in Chicago.

Lurbinectedin has also demonstrated to have an antitumoral activity in different solid tumors, being at the clinical development stage for the treatment of various tumors, such as pancreatic cancer and Ewing's Sarcoma. *"We will continue with the clinical development of this molecule, so as to be able offer new treatments to the patients suffering these cancers that are difficult to tackle,"* as highlighted by **José María Fernández Sousa-Faro, President of PharmaMar.**

At the next congress to be organized by the International Association for the Study of Lung Cancer (IASLC), and to be held in Toronto, Canada, new data will be presented on the overall survival of cohort B of patients from the phase I/II study with lurbinectedin in combination with doxorubicin for the treatment of Small-Cell Lung Cancer, trial that gave rise to the phase III ATLANTIS study.

PharmaMar is also negotiating with different companies from within the sector with the objective of beginning new studies with lurbinectedin in combination with immunotherapy.

Similarly, the Company will continue with the development of another two molecules; PM184 as a single agent in the 3rd line treatment of Colorectal Cancer and, also, as a single agent and in combinations for the treatment of other solid tumors; along with PM14 as a single agent and in combination for solid tumors.

New agreements have been closed by PharmaMar with other benchmark companies. PharmaMar has signed two licensing agreements for lurbinectedin. The first with Specialised Therapeutics Asia PTE., LTD, for Australia, New Zealand and a few other South East Asian countries; and the second, with Boryung Pharmaceutical Co. for South Korea. Two contracts were also signed for the licensing of Aplidin® (plitidepsin) with Eip Eczacibasi Ilac Pazarlama A.S., for Turkey, along with MegaPharm Ltd. for Israel. In 2018, PharmaMar announced the signing of a licensing agreement with Pint Pharma International for the commercialization and distribution of the same compound in Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, Mexico, Paraguay, Peru, Uruguay and Venezuela. A worldwide agreement for the development, production and commercialization of medicinal conjugates was also signed with Seattle Genetics Inc.

Sylentis

Under the framework of the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), held last May in Honolulu (Hawaii), Sylentis, belonging to PharmaMar Group, presented the results of the clinical studies carried

out using tivanisiran for dry eye syndrome, permitting the launch of the phase III HELIX trial, from which the final study data will be obtained during the last quarter of 2018. At the same congress the Company also presented preclinical results obtained from a new molecule administered topically (SYL1801) for the treatment of age associated macular degeneration, along with the preclinical results of a RNAi therapeutic that demonstrated how SYL116011 acted on seasonal allergies.

GENOMICA

Company leader in the field of molecular diagnostics and genetic identification, GENOMICA has obtained the approval from the Korean Regulatory Agency for the commercialization of the CLART[®] HPV (Human Papillomavirus) diagnostic kit.

With regards to the field of oncology, the Company has actively worked on the efficient development of a liquid biopsy test, obtaining a compatibility with the GENOMICA - CLART[®] diagnostic kit, targeting the Epidemical Growth Factor Receptor (EGFR BL), this allowing for the detection of mutations, accelerating a correct and rapid diagnosis with only a simple blood analysis.

Progress was made in the line of “pharmaco-accompanied diagnostics,” together with oncological compounds that permit the optimization and a correct patient administration through the analysis of specific gene panels.

Moreover, within the Company’s international expansion strategy, GENOMICA has opened affiliates in both Brazil and China, with the purpose of commercializing its products directly within the country.

Consumer Chemicals

Within the Consumer Chemicals’ sector, PharmaMar is comprised of two large Companies, Zelnova Zeltia and Xylazel, representing 40% (72M€) of the group’s income for 2017.

Zelnova Zeltia commercializes domestic insecticides and air fresheners along with other products for home care. Net Sales have increased by 1M€, obtaining their best sales results since 2011, and in both France and Italy, are leaders in the field of agrobiolology.

Xylazel, that manufactures and distributes varnishes, wood and metal protectors, along with paint used in interior decorating, obtained a net income in 2017 of 20.5M€, 6% more than the previous year (19.4M€).

PharmaMar's dedication to R&D in 2017

According to PharmaMar's President, **José María Fernández Sousa-Faro**, *"in 2017 a large number of objectives were accomplished that had been targeted, along with many important milestones which we are convinced will be reached in the new future; however, during the last year we have also seen difficult moments such as the CHMP's and the EMA's negative opinion for the commercialization of plitidepsin."*

The financial situation has allowed the Company to maintain its net investment in R&D in 2017 at approximately 78.5M€, surpassing the investment made in 2016, which was, up to that moment, the highest in the Company's history. The Oncology Business Unit has received 90% of that investment, this allowing continuing with the development of its promising molecules.

In the oncology area 71.2M€ were invested in 2017, mainly, to continue with the ongoing, randomized, pivotal phase III ATLANTIS study of lurbinectedin in Small-Cell Lung Cancer, in accordance with the recommendations of the Independent Data Monitoring Committee (IDMC). Last year the clinical development stage of a new molecule, PM14, started.

Moreover, Yondelis[®] share in soft tissue sarcoma in Europe remains constant, signifying more than a half of the Group's net sales. The sales of this compound have led to a net income of 84.6M€, 52% of the Group's total net sales for 2017.

The revenues from the licensing and drug development agreements signed with various different PharmaMar partners were achieved up to a total amount of 16.7 million euros.

About PharmaMar

Headquartered in Madrid, PharmaMar is a world-leading biopharmaceutical company in the discovery and development of innovative marine-derived anticancer drugs. The company has a pipeline of drug candidates and a robust R&D oncology program. PharmaMar develops and commercializes YONDELIS[®] in Europe and has other clinical-stage programs under development for several types of solid and

hematological cancers, Zepsyre® (PM1183), plitidepsin, PM184 and PM14. PharmaMar is a global biopharmaceutical company with subsidiaries in Germany, Italy, France, Switzerland, United Kingdom, Belgium, Austria and the United States. PharmaMar fully owns other companies: GENOMICA, a leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and two other chemical enterprises, Zelnova Zeltia and Xylazel. To learn more about PharmaMar, please visit us at www.pharmamar.com.

Disclaimer

This document is a press release, not a prospectus. This document does not constitute or form part of an offering or invitation to sell or a solicitation to purchase, offer or subscribe shares of the company. Moreover, no reliance should be placed upon this document for any investment decision or contract and it does not constitute a recommendation of any type with regard to the shares of the company.

Media Contact:

Alfonso Ortín – Communications Director aortin@pharmamar.com Mobile: +34 609493127
Miguel Martínez-Cava – Digital Communication Manager mmartinez-cava@pharmamar.com Mobile: +34 606597464
Phone: +34 918466000



Investor Relations:

Phone: +34 914444500

Or please visit our website at www.pharmamar.com